2Sawada M,Tsurumi H,Yamada T,et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy[J]. Eur J Haematol,2002,68(6): 被引量：1
3Shipp MA, Mauch PM, Harris NL. Non-Hodgkin's lymphomas[A]. In: Devita VT Jr, Hellmen S, Rosenberg SA, eds. Cancer, principles and practice of oncology[M].5ed. Philadelphia:New York :Lippincott-Raven. 1997:2165-2220. 被引量：1
4Tirelli U, Errante D, Van GM, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of 被引量：1
5Ezzat AA, Ibrahim EM, Stuart RK, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial[J]. Med Oncol,2000,17(1): 39-46. 被引量：1
6Brade WP, Herdrich K, Varini M, et al. Ifosfamide-pharmacology, safety and theraputic potential[J]. Cancer Treat Rev,1985,12(1):1-47. 被引量：1
7Pohlman B. Ifosfamide in the treatment of non-Hodgkin's lymphoma[J]. Semin Oncol, 1996,23(3 Suppl 6): 27-32. 被引量：1
8Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J]. N Engl J Med,1993,328(14):1002-1006. 被引量：1
9Haim N, Drumea K,Epelbaum R,et al. Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma[J]. Am J Clin Oncol,1999,22(1): 47-50. 被引量：1
10Reiser M,Bredenfeld H,Engert A,et al. The role of ifosfamide in the treatment of relapsed and refractory lymphoma[J]. Eur J Haematol,2001,Suppl (64): 37-40. 被引量：1
